The Danish approach to standards for economic evaluation methodologies

PharmacoEconomics

Volumn 12, Issue 6, 1997, Pages 627-636

  Alban, Anita ^a   Gyldmark, Marlene ^a   Pedersen, Arne Vesth ^b   Søgaard, Jes ^c  

^a Dansk Sundhedsinstitut   (Denmark)

^b Funen County Health Secretariat ^*  (Denmark)

^c UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; DENMARK; ECONOMIC EVALUATION; HEALTH SERVICE; MEDICAL TECHNOLOGY; METHODOLOGY; PHARMACOECONOMICS; PRACTICE GUIDELINE; PRIORITY JOURNAL; STANDARDIZATION;

EID: 0030691835     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-199712060-00003     Document Type: Article

References (16)

1. Australian Commonwealth Department of Health, Housing and Community Services. Guidelines for the pharmaceutical industry on preparation of submissions to the Pharmaceutical Benefits Advisory Committee, Canberra. Government Publ., 1992
2. Canadian Coordinating Office for Health Technology Assessment. Guidelines for economic evaluation of pharmaceuticals. 1 st ed. Ottawa: Canadian Coordinating Office for Health Technology Assessment, 1994
3. MEFA (Association of Danish Pharmaceutical Industry). Tal og data. København: MEFA, 1996
4. Finansministeriet (Danish Ministry of Finance). Udviklingen i medicinudgifterne. København: Finansministeriet, 1994
5. Alban A, Gyldmark M, Pedersen AV, et al. Sundhedsøkonomiske analyser af lægemidler. København: Schultz, 1995
6. Gold MR, Siegel JE, Russell LB, et al., editors. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996
7. Lehmann Knudsen J, Lange M, Prioritering i sundhedsvæsenet: sundhedsfaglig planlægning og prioritering at svangreprofylakse. København: Dansk Sygehus Institut (DSI), 1994. DSI report no.: 94.07
8. Lehmann Knudsen J, Lange M, Prioritering i sundhedsvæsenet: sundhedsfaglig planlægning og prioritering at svangreprofylakse. København: Dansk Sygehus Institut (DSI), 1994. DSI report no.: 94.07
9. Rice DP. Estimating the cost of illness. Washington, DC: US Department of Health. Education, and Welfare, Division of Medical Care Administration, 1966. Health economics series no.: 6
10. Rice DP. Estimating the cost of illness. Washington, DC: US Department of Health. Education, and Welfare, Division of Medical Care Administration, 1966. Health economics series no.: 6
11. Koopmanschap MA, van Ineveld BM. Towards a new approach for estimating indirect costs of disease. Soc Sci Med 1992; 34 (9): 1005-10
12. Koopmanschap MA, Rutten FHH. Indirect costs in economic studies: confronting the confusion. Pharmacoeconomics 1993; 4 (6): 446-54
13. Feeny D, Labelle R, Torrance GW. Integrating economic evaluations and quality of life assessments. In: Spilker B, editor. Quality of life assessments in clinical trials. New York: Raven Press, 1990: 71-83
14. Patrick DL, Deyo RA. Generic and disease-specific measures in assessing health status and quality of life. Med Care 1989; 27 (3 Suppl.): S217-32
15. Andersson F. Why is the pharmaceutical industry investing increasing amounts in health economic evaluations? Int J Technol Assess Health Care 1995; 11 (4): 750-61
16. Alban A, Nissen A. The basis for guidelines on economic appraisal of drugs and the management of guidelines in the post-marketing phase. Proceedings of a Nordic workshop on health economic evaluation of medicines; 1995 Mar 7-8: Stockholm. Uppsala: Nordic Council on Medicines, 1995: 37-41, NLN publication no.: 38